Dacomitinib
.svg)
Drug Status
Government Approvals
US(FDA), UK(BNF)
WHO Essential Medicine
NO
Known Teratogen
No
Pharmaceutical Class
NA
Controlled Drug Substance
No
Dacomitinib
Summary
Dacomitinib is used to treat a specific type of lung cancer known as non-small cell lung cancer (NSCLC) that has certain genetic mutations.
Dacomitinib works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps to slow or stop the spread of cancer cells.
The usual daily dose for adults is 45 mg, taken orally once daily. The safety and effectiveness in children have not been established.
Common side effects include diarrhea, rash, and decreased appetite. Serious adverse effects can include lung disease and severe diarrhea.
Dacomitinib can cause fetal harm, so it should not be used during pregnancy. Women should not breastfeed while taking this medication and for at least 17 days after the last dose. It can also interact with certain medications, so it's important to tell your doctor about all the medications you're taking.
Indications and Purpose
How does Dacomitinib work?
Dacomitinib is a kinase inhibitor that blocks the action of an abnormal protein involved in the growth and spread of cancer cells. By inhibiting this protein, Dacomitinib helps to slow or stop the progression of cancer.
Is Dacomitinib effective?
Dacomitinib has been shown to be effective in treating non-small cell lung cancer (NSCLC) with specific EGFR mutations. Clinical trials demonstrated a significant improvement in progression-free survival compared to other treatments, indicating its effectiveness in slowing the progression of cancer.
What is Dacomitinib?
Dacomitinib is used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, helping to slow or stop the spread of cancer cells. It is taken orally, usually once daily.
Directions for Use
For how long do I take Dacomitinib?
Dacomitinib is typically used until disease progression or unacceptable toxicity occurs. The duration of use can vary based on individual response and tolerance to the medication. Always follow your doctor's guidance on how long to continue treatment.
How do I take Dacomitinib?
Dacomitinib should be taken once daily, at the same time each day, with or without food. There are no specific food restrictions, but it is important to follow your doctor's instructions and discuss any dietary concerns with them.
How should I store Dacomitinib?
Dacomitinib should be stored in its original container, tightly closed, at room temperature away from excess heat and moisture. It should be kept out of reach of children to prevent accidental ingestion.
What is the usual dose of Dacomitinib?
The usual daily dose of Dacomitinib for adults is 45 mg taken orally once daily. The safety and effectiveness of Dacomitinib in children have not been established, so there is no recommended dose for pediatric patients. Always follow your doctor's advice for dosing.
Warnings and Precautions
Can Dacomitinib be taken safely while breastfeeding?
Women should not breastfeed while taking Dacomitinib and for at least 17 days after the last dose due to the potential for serious adverse reactions in breastfed infants. Consult your doctor for advice on feeding your baby during this time.
Can Dacomitinib be taken safely while pregnant?
Dacomitinib can cause fetal harm and should not be used during pregnancy. Women of reproductive potential should use effective contraception during treatment and for at least 17 days after the last dose. If pregnancy occurs, contact your doctor immediately.
Can I take Dacomitinib with other prescription drugs?
Dacomitinib can interact with medications that affect stomach acid, such as proton pump inhibitors and H2-receptor antagonists. It can also increase the concentration of drugs metabolized by CYP2D6, potentially leading to increased side effects. Always inform your doctor of all medications you are taking.
Is Dacomitinib safe for the elderly?
Elderly patients (65 years and older) may experience a higher incidence of severe side effects, more frequent dose interruptions, and more frequent discontinuations of Dacomitinib. It is important for elderly patients to be closely monitored by their healthcare provider to manage any adverse reactions effectively.
Who should avoid taking Dacomitinib?
Important warnings for Dacomitinib include the risk of interstitial lung disease, severe diarrhea, and dermatologic reactions. Patients should be monitored for these conditions, and treatment should be adjusted if they occur. Dacomitinib can also cause fetal harm, so it should not be used during pregnancy.
Forms / Brands
